Esperion Therapeutics, Inc. (ESPR): Price and Financial Metrics

Esperion Therapeutics, Inc. (ESPR): $5.80

0.29 (+5.26%)

POWR Rating

Component Grades













Add ESPR to Watchlist
Sign Up

Industry: Biotech



in industry


  • ESPR scores best on the Growth dimension, with a Growth rank ahead of 91.58% of US stocks.
  • The strongest trend for ESPR is in Growth, which has been heading up over the past 179 days.
  • ESPR ranks lowest in Stability; there it ranks in the 2nd percentile.

ESPR Stock Summary

  • Revenue growth over the past 12 months for Esperion Therapeutics Inc comes in at -65.53%, a number that bests only 2.22% of the US stocks we're tracking.
  • In terms of volatility of its share price, ESPR is more volatile than 97.85% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ESPR comes in at -86.18% -- higher than that of only 4.72% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Esperion Therapeutics Inc are LMNL, JAGX, CLPT, WB, and EYPT.
  • Visit ESPR's SEC page to see the company's official filings. To visit the company's web site, go to

ESPR Valuation Summary

  • In comparison to the median Healthcare stock, ESPR's price/sales ratio is 48.02% lower, now standing at 5.9.
  • Over the past 100 months, ESPR's price/sales ratio has gone NA NA.
  • ESPR's price/sales ratio has moved NA NA over the prior 100 months.

Below are key valuation metrics over time for ESPR.

Stock Date P/S P/B P/E EV/EBIT
ESPR 2021-08-31 5.9 -1.2 -1.1 -2.3
ESPR 2021-08-30 5.9 -1.2 -1.1 -2.3
ESPR 2021-08-27 6.2 -1.3 -1.2 -2.3
ESPR 2021-08-26 6.0 -1.2 -1.2 -2.3
ESPR 2021-08-25 6.2 -1.3 -1.2 -2.3
ESPR 2021-08-24 6.2 -1.3 -1.2 -2.3

ESPR Growth Metrics

    The year over year cash and equivalents growth rate now stands at 44.99%.
  • The 4 year cash and equivalents growth rate now stands at 303.99%.
  • The year over year price growth rate now stands at -36.97%.
ESPR's revenue has moved up $78,447,000 over the prior 70 months.

The table below shows ESPR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 78.447 -263.809 -269.108
2021-09-30 72.684 -274.653 -308.465
2021-06-30 62.108 -292.155 -324.516
2021-03-31 233.685 -104.898 -156.237
2020-12-31 227.547 -85.177 -143.551
2020-09-30 218.891 -66.621 -101.021

ESPR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ESPR has a Quality Grade of C, ranking ahead of 47.39% of graded US stocks.
  • ESPR's asset turnover comes in at 0.214 -- ranking 191st of 680 Pharmaceutical Products stocks.
  • CLDX, JAGX, and CDMO are the stocks whose asset turnover ratios are most correlated with ESPR.

The table below shows ESPR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.214 0.911 -0.853
2021-03-31 0.770 0.982 -0.522
2020-12-31 0.817 0.989 -0.694
2020-09-30 0.898 0.997 -0.670
2020-06-30 0.882 0.998 -0.566
2020-03-31 0.020 0.994 -2.191

ESPR Price Target

For more insight on analysts targets of ESPR, see our ESPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.91 Average Broker Recommendation 1.86 (Hold)

ESPR Stock Price Chart Interactive Chart >

Price chart for ESPR

ESPR Price/Volume Stats

Current price $5.80 52-week high $26.77
Prev. close $5.51 52-week low $3.28
Day low $5.38 Volume 563,300
Day high $5.85 Avg. volume 1,329,274
50-day MA $5.48 Dividend yield N/A
200-day MA $7.16 Market Cap 365.44M

Esperion Therapeutics, Inc. (ESPR) Company Bio

Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. The company was founded in 1998 and is based in Ann Arbor, Michigan.

ESPR Latest News Stream

Event/Time News Detail
Loading, please wait...

ESPR Latest Social Stream

Loading social stream, please wait...

View Full ESPR Social Stream

Latest ESPR News From Around the Web

Below are the latest news stories about Esperion Therapeutics Inc that investors may wish to consider to help them evaluate ESPR as an investment opportunity.

Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference

ANN ARBOR, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in addition to one-on-one investor meetings with other members of management, at the upcoming Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022. Event:Cowen 42nd Annual Healthcare ConferenceDate:Tuesday, March 8, 2022Format:Virtual Panel and 1:1 MeetingsPanel:Cardiometabolic/NASHTime:12:

Yahoo | February 24, 2022

Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%

Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.

Yahoo | February 23, 2022

Esperion Therapeutics GAAP EPS of -$1.77 beats by $0.52, revenue of $15.4M beats by $0.92M

Esperion Therapeutics press release (NASDAQ:ESPR): Q4 GAAP EPS of -$1.77 beats by $0.52. Revenue of $15.4M (+59.8% Y/Y) beats by $0.92M. As of December 31, 2021, cash, cash equivalents, restricted cash and investment securities available-for-sale totaled $309.3 million compared with $305.0 million on December 31, 2020. 2022 Financial Outlook: Research and...

Seeking Alpha | February 22, 2022

Esperion Therapeutics (ESPR) Q4 2021 Earnings Call Transcript

Thank you, operator, good morning and welcome to Esperion fourth quarter and full year 2021 financial results and company update conference call. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business.

Yahoo | February 22, 2022

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Read More 'ESPR' Stories Here

ESPR Price Returns

1-mo 6.23%
3-mo 38.42%
6-mo -25.45%
1-year -71.29%
3-year -88.82%
5-year -82.33%
YTD 16.00%
2021 -80.77%
2020 -56.40%
2019 29.63%
2018 -30.13%
2017 425.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1056 seconds.